全甲状腺切除术后乳头状甲状腺癌的动态风险评估:非刺激血清甲状腺球蛋白水平与甲状腺球蛋白倍增率
该回顾性研究纳入1818例Tg抗体阴性、无远处转移的乳头状甲状腺癌全甲状腺切除术后患者,术后1-3个月在TSH抑制下测定非刺激甲状腺球蛋白(uTg),并计算Tg倍增率(Tg-DR)。中位随访7.2年,发现uTg≥3 ng/mL与局部和远处复发风险增加独立相关;基于uTg和Tg-DR的四分类可区分淋巴结和远处复发的风险层级。
要点
- 术后uTg≥3 ng/mL与局部和远处复发风险显著增加独立相关。
- uTg和Tg-DR联合分类可区分淋巴结和远处复发风险层级。
- 上述指标有助于Tg-Ab阴性PTC患者术后动态风险分层。
核心结论
- 术后非刺激甲状腺球蛋白(uTg)和甲状腺球蛋白倍增率(Tg-DR)在Tg抗体阴性、TSH抑制下的乳头状甲状腺癌全甲状腺切除术后患者中具有预后价值。
研究设计与样本
- 回顾性研究纳入1818例Tg抗体阴性、无远处转移、行根治性全甲状腺切除术的乳头状甲状腺癌患者。
- 术后1-3个月在TSH抑制(<0.1 mIU/mL)下测定uTg;对术后TSH抑制下可测量3次以上Tg的患者计算Tg-DR。
主要发现
- 1818例中131例uTg≥3 ng/mL,单变量和多变量分析均显示其更易出现局部和远处复发(p < 0.001)。
- 在1212例无辅助放射性碘治疗且uTg和Tg-DR数据可用的患者中,淋巴结无复发生存率从A类到D类显著变差(A vs. B,p < 0.001,HR 5.083 [1.994-12.955];B vs. C,p = 0.001,HR 2.654 [1.462-4.824];C vs. D,p < 0.001,HR 27.420 [15.100-4.980])。
- B类与C类的远处无复发生存率(DR-FS)无差异(p = 0.419),D类DR-FS优于B和C类(p < 0.001),A类DR-FS较B和C类有更差趋势(p = 0.087)。
- A类、B和C类、D类可分别归类为远处复发高危、中危和低危。
关键数值与推荐
- uTg≥3 ng/mL为高风险阈值。
- Tg-DR≥0.33/年为高风险阈值。
- 四分类:A类uTg≥3 ng/mL且Tg-DR≥0.33/年;B类uTg<3 ng/mL且Tg-DR≥0.33/年;C类uTg≥3 ng/mL且Tg-DR<0.33/年;D类uTg<3 ng/mL且Tg-DR<0.33/年。
临床怎么用
- 对Tg抗体阴性、全甲状腺切除术后TSH抑制下的乳头状甲状腺癌患者,可检测术后uTg并计算Tg-DR以进行动态风险分层。
- 根据uTg和Tg-DR的四分类识别淋巴结和远处复发高风险患者,指导随访强度。
局限性
- 回顾性研究设计。
- 需要前瞻性研究证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Thyroglobulin (Tg), stimulated or unstimulated by recombinant human thyrotropin (TSH), is a static marker of recurrent or persistent disease, and the Tg-doubling rate (Tg-DR) is a dynamic prognostic factor. This study evaluated the prognostic value of an unstimulated Tg (uTg) and Tg-DR papillary thyroid carcinoma (PTC). Methods: This retrospective study included 1818 Tg antibody (Tg-Ab)-negative patients who underwent curative intent total thyroidectomy for PTC without distant metastasis. The uTg was measured 1-3 months post-surgery under TSH suppression (<0.1 mIU/mL). We calculated the Tg-DR for patients, of whom postoperative Tg levels could be measured three or more times under TSH suppression. Results: Eighty-eight (4.8%) and 32 (1.8%) patients had respective local and distant recurrences (median follow-up period, 7.2 years; 25th percentile 4.7 years, 75th percentile 9.8 years). Of 1818 patients, 131 had a uTg ≥3 ng/mL and were more likely to display local and distant recurrences in univariate and multivariable analyses (p < 0.001). We divided 1212 patients with no adjuvant radioactive iodine treatment, of whom uTg and Tg-DR data were available, into four categories A, uTg ≥3 ng/mL and Tg-DR ≥0.33/year; B, uTg <3 ng/mL and Tg-DR ≥0.33/year; C, uTg ≥3 ng/mL and Tg-DR <0.33/year; and D, uTg <3 ng/mL and Tg-DR <0.33/year. The lymph node recurrence-free survival rate was significantly worse from category A to D (A vs. B, p < 0.001, hazard ratio or HR [CI]: 5.083 [1.994-12.955]; B vs. C, p = 0.001, HR [CI]: 2.654 [1.462-4.824]; C vs. D, p < 0.001, HR [CI]: 27.420 [15.100-4.980]). The distant recurrence-free survival rate (DR-FS) of category B did not differ from that of category C (p = 0.419), but DR-FS of category D was better (p < 0.001) than those of B and C, and that of category A tended to be worse (p = 0.087) compared with those of B and C. Patients in category A, categories B and C, and category D could thus be classified as high-risk, intermediate-risk, and low-risk for distant recurrence, respectively. Conclusions: This study demonstrates the prognostic value of postoperative uTg and Tg-DR in Tg-Ab-negative patients with PTC under TSH suppression after total thyroidectomy. Prospective studies are needed to confirm these findings.
引用
- Ito Y, Miyauchi A, Yamamoto M, et al. Dynamic Risk Assessment Using Unstimulated Serum Thyroglobulin Level and Thyroglobulin Doubling Rate after Total Thyroidectomy for Papillary Thyroid Carcinoma. Thyroid. 2025. PMID: 40794485. doi:10.1177/10507256251367242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。